menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Enforcement Report - Week of March 26, 2025

    FDA

    Amgen, Kyowa Kirin Report Ph3 Rocatinlimab Data In Atopic Dermatitis

    PR NEWSWIRE

    Amgen’s late-stage obesity trials expected to read out in ‘27

    FIERCE BIOTECH

    Tezspire Treats Chronic Sinus Symptoms With Nasal Polyps

    PR NEWSWIRE

    AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

    PR NEWSWIRE

    Amgen to invest $200 million in India site, CEO says

    ECONOMICTIMES

    Drugmaker Amgen to invest $200 million in India site, CEO says

    REUTERS

    Amgen to Present at CITI`S 2025 Virtual oncology leadership summit

    PR NEWSWIRE

    Amgen, Ideaya Call It Quits on Cancer Combo

    BIOSPACE

    Accumulus Synergy Powers 1st Digitally Generated Dossier Worldwide

    GLOBENEWSWIRE

    Amgen’s early-stage obesity asset put on clinical hold by FDA

    FIERCE BIOTECH

    Amgen Reports Report Q4 and Full Year Financial Result

    PR NEWSWIRE

    EU Approves Blincyto® In CD19+ B-Cell ALL Consolidation Phase

    PR NEWSWIRE

    Amgen fends off Celltrion`s proposed Prolia biosim until June

    FIERCE PHARMA

    New Treatments for Celiac Disease Gain Traction

    BIOSPACE

    New Treatments for Celiac Disease Gain Traction

    BIOSPACE

    FDA Approves Lumakras & Vectibix Combo For G12C Colorectal Cancer

    PR NEWSWIRE

    FDA approves Amgen`s colorectal cancer therapy

    REUTERS

    Sling`s oral Tepezza rival hits goal in thyroid eye disease, Ph 3

    PR NEWSWIRE

    Sling`s oral Tepezza rival hits goal in thyroid eye disease

    FIERCE BIOTECH

    CytomX lays off 40%, mulls future of Amgen-partnered drug

    FIERCE BIOTECH

    Amgen’s IMDYLLTRA Gets UK Approval For Extensive-Stage Lung Cancer

    BUSINESSWIRE

    Amgen`s Biologic Kanjinti Receives Suppl Approval in US

    FDA

    BeiGene inks $150M deal to follow cancer trail blazed by Amgen

    FIERCE BIOTECH

    Amgen invests $1B in North Carolina manufacturing expansion

    BIOSPACE

    Blincyto Improves Survival In Pediatric B-ALL With Chemotherapy

    PR NEWSWIRE

    Amgen Stock Avoids Worst Day in 24 Years After Weight-Loss Data

    MARKETWATCH

    Amgen`s weight-loss drug fails to impress in study; shares plunge

    REUTERS

    Stanford`s Chang takes Amgen`s CSO reins from Bradner

    FIERCE BIOTECH

    Amgen`s Biologic Repatha Receives Suppl Approval in US

    FDA

    Amgen Presents New Data on Rare Inflammatory Diseases at ACR 2024

    PR NEWSWIRE

    Amgen dismisses bone density concerns to its weight-loss drug

    REUTERS

    BMS, Merck, Amgen & more face near-term generic woes: Leerink

    FIERCE PHARMA

    Amgen, AZ`s Tezspire excels in phase 3 rhinosinusitis trial

    FIERCE PHARMA

    AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

    PR NEWSWIRE

    Amgen reaps Horizon buyout rewards in Q3, preps biosim launches

    FIERCE PHARMA

    Amgen Whets Investors’ Appetites for MariTide Obesity Data by EoY

    BIOSPACE

    Amgen disappears lung disease program after phase 2 fail

    FIERCE BIOTECH

    AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

    PR NEWSWIRE

    Amgen gears up to launch Eylea biosim as Regeneron plots appeal

    FIERCE PHARMA

    AMGEN Presents Phase 3 Data For UPLIZNA® In Generalized Myasthenia

    PR NEWSWIRE

    Amgen can`t sidestep investor lawsuit over $10.7B tax bill

    FIERCE PHARMA

    La La Anthony Partners With Amgen on Plaque Psoriasis Insight

    PR NEWSWIRE

    Amgen must face lawsuit claiming it hid $10.7 billion tax bill

    REUTERS

    Amgen scores late trial success for eczema and MG treatments

    STATNEWS

    Regeneron loses bid to block Amgen`s Eylea biosim, sinking shares

    FIERCE PHARMA

    Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

    REUTERS

    Amgen And Merck Join Academic Clinical Trial Diversity Initiative

    FIERCE BIOTECH

    AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

    PR NEWSWIRE

    Viridian`s Drug Resolves Eye Disease Symptoms, Challenges Amgen`s Tepezza

    FIERCE BIOTECH

    Big Pharma Backs OAC`s `Your Weight Matters` Campaign Challenge

    FIERCE PHARMA

    Amgen Shares New Imdelltra Data In Small Cell Lung Cancer At WCLC 2024

    PR NEWSWIRE

    Amgen Plans Phase III Program for Next-Gen Obesity Drug Targeting Liver and Kidney Diseases

    BIOSPACE

    AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE

    PR NEWSWIRE

    BioMarin Brings on Roche, Amgen Alums in Executive Restructuring

    BIOSPACE

    Roche Regains Reputation Crown Among Rare Disease Patient Groups

    FIERCE PHARMA

    OTEZLA Now Available In US For Pediatric Plaque Psoriasis

    PR NEWSWIRE

    Amgen`s Biologic Repatha (Evolocumab) Receives Suppl Approvals in US

    FDA

    Amgen`s Biologic Amjevita (Adalimumab) Receives Suppl Approvals in US

    FDA

    Biden, Harris hail Medicare drug price cuts that will save billions

    REUTERS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.